CORAL GABLES, FL, October 4, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical co mpany focused on the development and commercialization of novel prescription drugs ta rgeting rare (orphan) neuromuscular and neurological diseases, today announced that Pa trick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer a nd Chief Scientific Officer, will present at the 12 th Annual BIO Investor Forum being held at Th e Palace Hotel in San Francisco, California, October 8-9. The presentation is scheduled for Tuesday, October 8 th at 9:00 am (PDT). The presentation materials will be posted at www.cat alystpharma.com in the Investors section under Events & Presentations.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targ eting rare (orphan) neuromuscular and neurological diseases, in cluding Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial and recently received “Breakthrough Thera py Designation” from the U.S. Food and Drug Administration (FDA). Catalyst is also developing a potentially sa fer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epile psy, as well as other neurological conditions associated with reduced GABAergic si gnaling, like post-traumatic stress disorder and Tourette Syndrome.
Forward-Looking Statements
This press release contains fo rward-looking statements. Forwar d-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted resu lts. A number of factors, including the timing of completion of Catalyst’s currently ongoing Phase III trial of Firdapse™, whether the Phase III trial will be successful, whether the receipt of breakthrough therapy designation for Firdapse™ will expedite the development and review of Fir dapse™ by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether any of Catalyst’s product candidates will ever be ap proved for commercialization or successfully commercialized, and those other factors describe d in Catalyst’s Annua l Report on Form 10-K for the fiscal year 2012 and other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Ca talyst. Copies of Catalyst’s fil ings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undert ake any obligation to update the information contained herein, which speaks only as of this date.
Help employers find you! Check out all the jobs and post your resume.
